Volume 9, Issue 2 (spring & summer 2014)
ijpd 2014, 9(2): 25-30 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Eskandarian T, Eftekharian Jahromi H, Soleymanzade R. Evaluation of sedative effect and safety of pregabalin in uncooperative children in dental clinic. ijpd 2014; 9 (2) :25-30
URL: http://jiapd.ir/article-1-38-en.html
URL: http://jiapd.ir/article-1-38-en.html
Abstract: (7762 Views)
Background and Aims: Treatment of uncooperative children is achallenging issue in pediatric dentistry. Pedodontistsare interested in medications with mild sedative effects. The aim of the current study was to evaluate the sedative effect and safety of pregabalin in uncooperative children. Materials and Methods: Twenty-one children were included in this randomized crossover, double-blinded placebo-controlled clinical trial. Each child participated in two separated dental visits. Pregabalin or placebo was given randomly at the first visit and the alternative was used at the second visit. Ramsay Sedation Scale and Frankl behavioral rating scale were using to evaluate the efficacy of the premedication. These scales were scored 2.5hours after premedication. The data were analyzed with the Mann-Whitney U test. The comparison of the number of the “successful” treatments was done using the Chi-square test. Monitoring of the vital signs was done under the supervision of an anesthesiologist throughout the treatment procedure. Results: Sedation level of the children during the dental treatment was significantly higher in the pregabalin group than in the placebo group (p=0.007). The Children’s behavioral rating score during the dental treatment was not significantly different between the two groups (p=0.067). The number of treatments which are finished “successfully” was more in the pregabalin group (p=0.013). Children’s vital signs during the entire treatment procedure were within the normal range. Conclusion: Pregabalin provides sufficient safety in children. A significant sedative effect is anticipated to be seen from 2.5 hours after orally given pregabalin in children. Sedative effect of pregabalin results in more successful treatment procedures in uncooperative children.
Type of Article: Research Article |
Subject:
General
Received: 2015/01/28 | Accepted: 2015/01/28 | Published: 2015/01/28
Received: 2015/01/28 | Accepted: 2015/01/28 | Published: 2015/01/28
References
1. Klingberg G, Raadal M, Anrup K. Dental Fear and Behavior Management Problems. In: Koch G, Poulsen S. Pediatric Dentistry: A clinical approach. 2nd ed. UK: Blackwell; 2009.
2. DeanJA,AveryDR,McDonald RE. Dentistryfor the Child and Adolescent.9th ed. USA: Mosby; 2011.
3. Millan MJ. The neurobiology and control of anxious states. Progress in Neurobiology. 2003;70(2):83-244. [DOI:10.1016/S0301-0082(03)00087-X]
4. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. ClinTher. 2007;29:26-48. [DOI:10.1016/j.clinthera.2007.01.013]
5. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52(4):1264-73. [DOI:10.1002/art.20983]
6. White PF, Tufanogullari B, Taylor J, Klein K. The effect of pregabalin on preoperative anxiety and sedation levels: a dose-ranging study. Anesthesia & Analgesia. 2009; 108(4): 1140-5. [DOI:10.1213/ane.0b013e31818d40ce]
7. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the Novel Anxiolytic Pregabalin in Social Anxiety Disorder: A Placebo-Controlled, Multicenter Study. J ClinPsychopharmacol. 2004;24(2):141-9. [DOI:10.1097/01.jcp.0000117423.05703.e7]
8. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double blind, placebo-controlled comparison of BID versus TID dosing. J ClinPsychopharmacol. 2005;25(2):151-8. [DOI:10.1097/01.jcp.0000155820.74832.b0]
9. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized double blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67(5):771-82. [DOI:10.4088/JCP.v67n0511]
10. Montgomery SA. Pregabalin for the treatment of generalized anxiety disorder. Expert Opin. Pharmacother. 2006;7(15): 2139-54. [DOI:10.1517/14656566.7.15.2139]
11. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalizedanxiety disorder: a 4-week, multicenter, double-blind, placebo controlled trial of pregabalin and alprazolam. Arch of Gen Psychiatry. 2005;62(9): 1022-30. [DOI:10.1001/archpsyc.62.9.1022]
12. Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J ClinPsychopharmacol. 2007;27(3):263-72. [DOI:10.1097/jcp.0b013e318059361a]
13. Nutt D, Mandel F, Baldinetti F. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model. J Psychopharmacol. 2009;23(8):867-73. [DOI:10.1177/0269881108094722]
14. Vondracek P, Oslejskova H, Kepak T, Mazanek P, Sterba J, Rysava M, et al. Efficacy of pregabalin in neuropathic pain in pediatric oncological patients. Eur J Pediatr Neurol. 2009;13(4):332-6. [DOI:10.1016/j.ejpn.2008.06.011]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
